Sikorska Beata, Danilewicz Marian, Wagrowska-Danilewicz Małgorzata
Department of Pathomorphology, Morphometry Division, Medical University, Łódź.
Pol J Pathol. 2002;53(1):17-24.
In several tumours expression of CD44 and nm23 protein has been linked to tumour progression and metastasis. The aim of this study was to determine if there is any relationship between CD44v6 and nm23 protein immunoreactivity in squamous cancer cells and prognosis in patients with laryngeal carcinoma. The samples of human larynx cancer from patients with lymph node metastases and without lymph node involvement were analysed for CD44v6 and nm23 protein expression by immunohistochemistry using monoclonal antibodies. There was no significant difference in CD44v6 immunoexpression in cancer cells in patients with and without metastases. The statistical analysis did not reveal difference in survival time between patients with high and low CD44v6 immunoreactivity. The expression of nm23 protein in laryngeal cancer in patients with lymph node metastases was significantly decreased in comparison with patients without metastases. Analysis of survival revealed that patients with lower expression of nm23 protein in tumour tissue had significantly shorter survival than patients with higher nm23 immunoreactivity. The results suggest that nm23 protein immunoreactivity can be useful in predicting tumour behaviour in laryngeal cancer patients and indicate a lack of association between CD44v6 immunoexpression and tumour progression in those patients.
在多种肿瘤中，CD44和nm23蛋白的表达与肿瘤进展和转移相关。本研究的目的是确定在喉癌细胞中CD44v6和nm23蛋白免疫反应性之间是否存在任何关系，以及其与喉癌患者预后的关系。采用单克隆抗体免疫组织化学法分析有淋巴结转移和无淋巴结受累的喉癌患者的人喉癌样本中CD44v6和nm23蛋白的表达。有转移和无转移患者的癌细胞中CD44v6免疫表达无显著差异。统计学分析未显示CD44v6免疫反应性高和低的患者在生存时间上有差异。与无转移患者相比，有淋巴结转移的喉癌患者中nm23蛋白的表达显著降低。生存分析显示，肿瘤组织中nm23蛋白表达较低的患者的生存期明显短于nm23免疫反应性较高的患者。结果表明，nm23蛋白免疫反应性可用于预测喉癌患者的肿瘤行为，并表明这些患者中CD44v6免疫表达与肿瘤进展之间缺乏关联。
